1175512-08-9

Basic information

• Product Name: Methyl 5-broMo-4-hydroxynicotinate
• Synonyms: Methyl 5-broMo-4-hydroxynicotinate
• CAS NO: 1175512-08-9
• Molecular Formula: C₇H₆BrNO₃
• Molecular Weight: 232.03144
• Mol File: 1175512-08-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 309.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.737±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 7.45±0.69(Predicted)
• CAS DataBase Reference: Methyl 5-broMo-4-hydroxynicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-broMo-4-hydroxynicotinate(1175512-08-9)
• EPA Substance Registry System: Methyl 5-broMo-4-hydroxynicotinate(1175512-08-9)

Safety Data

• Hazardous Substances Data: 1175512-08-9(Hazardous Substances Data)

Usage

General Description

Methyl 5-bromo-4-hydroxynicotinate is a chemical compound with the molecular formula C7H6BrNO3. It is a derivative of nicotinic acid, also known as vitamin B3, and contains a bromine atom and a hydroxyl group on the pyridine ring. Methyl 5-broMo-4-hydroxynicotinate is commonly used in organic synthesis and medicinal chemistry, particularly as a building block for the synthesis of pharmaceuticals and agrochemicals. It can also be utilized as a reagent in various chemical reactions, including Suzuki-Miyaura cross-coupling and palladium-catalyzed C-H functionalization. Methyl 5-bromo-4-hydroxynicotinate is a valuable compound with diverse applications in the field of organic chemistry.

InChI:InChI=1S/C7H6BrNO3/c1-12-7(11)4-2-9-3-5(8)6(4)10/h2-3H,1H3,(H,9,10)

Upstream product

• 67-56-1 methanol 
• 1052114-83-6 5-bromo-4-hydroxypyridine-3-carboxylic acid 

Downstream Products

• 1052114-81-4 5-(4-fluorophenyl)-4-oxo-1,4-dihydropyridin-3-ylcarboxylic acid 

Relevant articles and documents

Discovery of pyrrolopyridine-pyridone based inhibitors of met kinase: Synthesis, X-ray crystallographic analysis, and biological activities

Conformationally constrained 2-pyridone analogue 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors such as 3 and 4. The X-ray crystallographic data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogues was rationalized. Many of these analogues showed potent antiproliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC50 values of 4 and 27 nM, respectively. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model.